Marije E. Weidema

933 total citations
15 papers, 288 citations indexed

About

Marije E. Weidema is a scholar working on Oncology, Cardiology and Cardiovascular Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Marije E. Weidema has authored 15 papers receiving a total of 288 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 8 papers in Cardiology and Cardiovascular Medicine and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marije E. Weidema's work include Vascular Tumors and Angiosarcomas (12 papers), Cardiac tumors and thrombi (8 papers) and Sarcoma Diagnosis and Treatment (7 papers). Marije E. Weidema is often cited by papers focused on Vascular Tumors and Angiosarcomas (12 papers), Cardiac tumors and thrombi (8 papers) and Sarcoma Diagnosis and Treatment (7 papers). Marije E. Weidema collaborates with scholars based in Netherlands, United Kingdom and Germany. Marije E. Weidema's co-authors include Ingrid M.E. Desar, Yvonne M.H. Versleijen‐Jonkers, Uta Flucke, Winette T.A. van der Graaf, Melissa H.S. Hillebrandt-Roeffen, Myrra Vernooij‐Dassen, Raymond T.C.M. Koopmans, Marieke Perry, Bram Tilburgs and Yvonne Engels and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Clinical Cancer Research.

In The Last Decade

Marije E. Weidema

15 papers receiving 286 citations

Peers

Marije E. Weidema
Randa Loutfi United States
Kerry Schaffer United States
Hillary Heiling United States
Anna Plym Sweden
Victoria Huynh United States
Susan Flynn United States
Marije E. Weidema
Citations per year, relative to Marije E. Weidema Marije E. Weidema (= 1×) peers Grace Musto

Countries citing papers authored by Marije E. Weidema

Since Specialization
Citations

This map shows the geographic impact of Marije E. Weidema's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marije E. Weidema with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marije E. Weidema more than expected).

Fields of papers citing papers by Marije E. Weidema

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marije E. Weidema. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marije E. Weidema. The network helps show where Marije E. Weidema may publish in the future.

Co-authorship network of co-authors of Marije E. Weidema

This figure shows the co-authorship network connecting the top 25 collaborators of Marije E. Weidema. A scholar is included among the top collaborators of Marije E. Weidema based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marije E. Weidema. Marije E. Weidema is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Versleijen‐Jonkers, Yvonne M.H., Melissa H.S. Hillebrandt-Roeffen, Thijs van Dalen, et al.. (2023). Prognostic Factors in Epithelioid Hemangioendothelioma: Analysis of a Nationwide Molecularly/Immunohistochemically Confirmed Cohort of 57 Cases. Cancers. 15(13). 3304–3304. 4 indexed citations
2.
Versleijen‐Jonkers, Yvonne M.H., Melissa H.S. Hillebrandt-Roeffen, Marije E. Weidema, et al.. (2023). Establishment and characterization of the first patient-derived radiation-induced angiosarcoma xenograft model (RT-AS5). Scientific Reports. 13(1). 2653–2653. 3 indexed citations
3.
Versleijen‐Jonkers, Yvonne M.H., Melissa H.S. Hillebrandt-Roeffen, Marije E. Weidema, et al.. (2022). Immunological and Genomic Analysis Reveals Clinically Relevant Distinctions between Angiosarcoma Subgroups. Cancers. 14(23). 5938–5938. 14 indexed citations
4.
Weidema, Marije E., et al.. (2022). Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups. Immunologic Research. 70(2). 256–268. 13 indexed citations
5.
Husson, Olga, Marije E. Weidema, Markus Wartenberg, et al.. (2022). Setting the international research agenda for sarcoma together with patients and carers: first results of the Sarcoma Patient EuroNet (SPAEN) priority setting partnership. ESMO Open. 7(3). 100509–100509. 7 indexed citations
6.
Versleijen‐Jonkers, Yvonne M.H., Melissa H.S. Hillebrandt-Roeffen, Marije E. Weidema, et al.. (2022). Which angiosarcoma subtypes may benefit from immunotherapy?. Journal of Clinical Oncology. 40(16_suppl). 11572–11572. 1 indexed citations
7.
Weidema, Marije E., Ingrid M.E. Desar, Melissa H.S. Hillebrandt-Roeffen, et al.. (2021). PARP inhibition in UV-associated angiosarcoma preclinical models. Journal of Cancer Research and Clinical Oncology. 147(9). 2579–2590. 3 indexed citations
8.
Weidema, Marije E., Suzanne E. J. Kaal, Yvonne M.H. Versleijen‐Jonkers, et al.. (2021). The heterogeneity of Epithelioid Hemangioendothelioma (EHE): A case series and review of the literature with emphasis on treatment options. Seminars in Oncology. 48(2). 111–118. 11 indexed citations
9.
Husson, Olga, et al.. (2021). Supportive care needs of patients living with an extremely rare and unpredictable cancer: The Epithelioid Haemangioendothelioma patient experience. European Journal of Cancer Care. 30(6). e13461–e13461. 5 indexed citations
10.
Weidema, Marije E., Olga Husson, Winette T.A. van der Graaf, et al.. (2020). Health-related quality of life and symptom burden of epithelioid hemangioendothelioma patients: a global patient-driven Facebook study in a very rare malignancy. Acta Oncologica. 59(8). 975–982. 11 indexed citations
11.
Weidema, Marije E., Christian Koelsche, Ingrid M.E. Desar, et al.. (2019). DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas. Clinical Cancer Research. 26(1). 93–100. 32 indexed citations
12.
Weidema, Marije E., Uta Flucke, Winette T.A. van der Graaf, et al.. (2019). Prognostic Factors in a Large Nationwide Cohort of Histologically Confirmed Primary and Secondary Angiosarcomas. Cancers. 11(11). 1780–1780. 25 indexed citations
13.
Weidema, Marije E., Yvonne M.H. Versleijen‐Jonkers, Uta Flucke, Ingrid M.E. Desar, & Winette T.A. van der Graaf. (2019). Targeting angiosarcomas of the soft tissues: A challenging effort in a heterogeneous and rare disease. Critical Reviews in Oncology/Hematology. 138. 120–131. 24 indexed citations
14.
Tilburgs, Bram, Myrra Vernooij‐Dassen, Raymond T.C.M. Koopmans, et al.. (2018). The importance of trust-based relations and a holistic approach in advance care planning with people with dementia in primary care: a qualitative study. BMC Geriatrics. 18(1). 184–184. 62 indexed citations
15.
Versleijen‐Jonkers, Yvonne M.H., Melissa H.S. Hillebrandt-Roeffen, Mark A.J. Gorris, et al.. (2017). Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. Oncotarget. 8(41). 71371–71384. 73 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026